LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Atidarymo kaina

14.71 14.83

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.81

Max

14.97

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-154M -183M
Pelnas, tenkantis vienai akcijai	-0.6
Darbuotojai	103
EBITDA	-5.3M -37M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+57.87% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-10

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	249M 3.5B
Ankstesnė atidarymo kaina	-0.12
Ankstesnė uždarymo kaina	14.71

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-31 23:44; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

2026-05-31 23:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-31 23:36; UTC

Rinkos pokalbiai

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

2026-05-31 23:36; UTC

Rinkos pokalbiai

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

2026-05-31 22:54; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

2026-05-29 23:08; UTC

Įsigijimai, susijungimai, perėmimai

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026-05-29 23:06; UTC

Įsigijimai, susijungimai, perėmimai

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026-05-29 20:53; UTC

Uždarbis

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026-05-29 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 20:33; UTC

Rinkos pokalbiai

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026-05-29 20:11; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 19:47; UTC

Uždarbis

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026-05-29 19:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026-05-29 19:22; UTC

Rinkos pokalbiai

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026-05-29 19:05; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026-05-29 18:19; UTC

Rinkos pokalbiai

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026-05-29 18:12; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026-05-29 18:11; UTC

Rinkos pokalbiai

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026-05-29 18:10; UTC

Rinkos pokalbiai

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026-05-29 17:55; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 17:55; UTC

Rinkos pokalbiai

NEAR Protocol Nearly Doubles in May -- Market Talk

2026-05-29 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026-05-29 17:00; UTC

Uždarbis

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026-05-29 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-29 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-29 16:02; UTC

Rinkos pokalbiai

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026-05-29 15:55; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

57.87% į viršų

12 mėnesių prognozė

Vidutinis 20.27 USD 57.87%

Aukščiausias 30 USD

Žemiausias 9 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.